It was reported that expression of TP53 markedly enhanced the susceptibility to cisplatin and cisplatin-induced cell death in variable cancers [55–57], and we discovered that low TP53 expression in HNSCC was closely associated with higher IC50 of cisplatin while TP53 was proved to have negative correlation with PYGL in expression level. Here, TP53 is linked to head and neck squamous cell carcinoma.